COMP <GO>
ZBRA vs TMO // FORWARD P/E MULTIPLE
Zebra Technologies Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ZBRA 6
— TMO 9
▲ FORWARD P/E MULTIPLE LEADER: TMO
LAST: $361.26 (-4.27%) • MKT CAP: $17.85B
forward-pe
39.6x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZBRA VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZBRA | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 48.10% | 41.00% | +7.10 | ZBRA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.50% | 9.30% | +0.20 | ZBRA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.0x | 30.4x | -4.40 | ZBRA | /valuation <GO> |
| Free Cash Flow Yield | 4.65% | 2.40% | +2.25 | ZBRA | /fcf-yield <GO> |
| Operating Margin | 13.00% | 17.40% | -4.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.80% | 15.10% | -7.30 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 3.90% | +4.40 | ZBRA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.95 | 4.50 | -0.55 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.70% | +0.60 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.1 | 59.1 | -19.05 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.94 | +0.19 | ZBRA | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 39.6x | 36.3x | +3.30 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.85B | $262.22B | -$244.36B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZBRA REV | TMO REV | ZBRA GROSS % | TMO GROSS % | ZBRA FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.40B | $44.56B | 48.1% | 44.0% | $831.0M | $6.29B |
| FY 2024 | $4.98B | $42.88B | 48.4% | 44.0% | $954.0M | $7.27B |
| FY 2023 | $4.58B | $42.86B | 44.0% | 44.0% | -$210.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZBRA // BETA 1.13
TMO // BETA 0.94